Ryutaro Tanno Joins Pathos as Chief AI Officer to Advance AI-Driven Drug Development

Related stories

Pathos has appointed Ryutaro Tanno as its new Chief AI Officer (CAO), bringing experienced artificial intelligence research leadership to the company’s mission of transforming drug development. Tanno joins Pathos after four years at Google DeepMind, where he contributed to several healthcare AI initiatives, including Flamingo-CXR, Med-Gemini, AMIE, AI Co-Scientist, and AI Co-Clinician.

In his new role, Tanno will help advance Pathos’s AI-driven approach to pharmaceutical research and development, initially focused on oncology and now expanding into neurology. The company aims to use artificial intelligence to improve decisions around drug development, patient selection, and clinical trial execution.

A central part of Pathos’s strategy is Foundry, its proprietary AI platform. Rather than developing AI models and agents in isolation, Pathos integrates them into its own drug development operations. The platform supports decisions about which drug candidates to develop, which patient populations to prioritize, and how clinical trials should be conducted.

Also Read: Jonathan Wildman Joins Korn Ferry as President, Global Life Sciences

One of the distinguishing aspects of this approach is the feedback loop between AI and real-world research. Pathos feeds data from its clinical trials and laboratory activities back into Foundry, allowing the platform to incorporate new evidence into subsequent decisions. This creates an opportunity for continuous learning across drug development programs.

Pathos is also extending its AI capabilities beyond oncology into neurological conditions, including Alzheimer’s disease. Its recently announced collaborations with Bristol Myers Squibb and Tempus AI highlight this expansion and the growing role of AI and large-scale patient data in neuroscience research.

Tanno’s appointment brings deep experience in medical AI research and real-world healthcare applications to this mission. His move reflects a broader shift toward integrating AI directly into scientific and pharmaceutical workflows, where its value can be evaluated against laboratory findings and clinical outcomes.

As pharmaceutical companies explore AI-driven research, Pathos is positioning itself around a model that connects data, AI intelligence, and drug development decisions to improve the way new therapies are developed.

Subscribe

- Never miss a story with notifications


    Latest stories